Submodule
Patient, Indication, and Vascular Access
Pediatric PN starts with gestational and postnatal age, growth trajectory, gastrointestinal function, expected duration, fluid tolerance, and the smallest safe route that can deliver the required formulation.
- Preterm, neonatal, infant, child, and adolescent context
- Indications and enteral alternatives
- Peripheral and central access
- Umbilical and long-term devices
Gestation, age, weight, growth
→Deficit and enteral feasibility
→Peripheral, central, or umbilical
→Duration, goals, reassessment
Define the patient precisely
A 900 g preterm infant, a term neonate, a toddler, and a teenager do not share one default prescription. Gestational age, postmenstrual age, postnatal age, current weight, growth velocity, organ maturity, disease, and enteral exposure change nutrient demand and tolerance.
Use PN when the gut cannot yet meet the need
Common indications include necrotizing enterocolitis, gastroschisis, intestinal obstruction or dysmotility, short bowel syndrome, severe malabsorption, high-output fistula, prolonged ileus, and treatment-related gastrointestinal injury. PN supports the interval in which safe enteral delivery cannot meet the assessed goal. It does not remove the need to reassess enteral readiness.
Initiate preterm support promptly when appropriate
The 2023 ASPEN preterm guideline recommends prompt PN initiation after birth once appropriate vascular access is obtained. The evidence quality for timing is limited, so the prescription still accounts for clinical stability, substrate tolerance, available access, and the planned introduction of human milk or enteral feeding.
Match access to concentration and duration
Peripheral access limits final concentration and is vulnerable to infiltration and phlebitis. Central access supports concentrated therapy but introduces infection, thrombosis, malposition, and device risks. Umbilical venous catheters can provide early neonatal access when positioned and managed correctly. PICCs, tunneled catheters, and ports are selected according to duration, anatomy, care setting, and the need to preserve access.
Quick check
Submodule
Fluid, Dextrose, and Glucose Infusion Rate
Small changes in daily volume or dextrose concentration can produce large changes in neonatal fluid exposure, osmolarity, glucose delivery, and metabolic risk.
- Age-specific fluid planning
- Maintenance estimates and exceptional losses
- Dextrose grams and calories
- GIR calculation and tolerance
mg/kg/min
→weight and 1,440 minutes
→divide milligrams by 1,000
→glucose and clinical tolerance
Build a complete fluid ledger
Maintenance equations are starting estimates. Incubator losses, respiratory support, fever, diarrhea, ostomy or fistula output, drains, kidney function, medications, phototherapy, edema, and concurrent infusions can change the plan. Count nutrition, medicines, carrier fluids, flushes, blood products, and enteral intake in the same daily ledger.
Calculate dextrose in both directions
To convert GIR to grams per day, multiply mg/kg/min by weight and 1,440 minutes, then divide by 1,000 mg/g. To calculate GIR from grams per day, multiply grams by 1,000 and divide by weight and total infusion minutes. Intravenous dextrose provides 3.4 kcal/g.
Advance according to response
Neonates often require a higher GIR than adults because glucose supports rapid growth and a relatively large brain. However, a lecture range is not an automatic target. Glucose trends, insulin exposure, sepsis, corticosteroids, stress, hepatic function, respiratory status, and all dextrose sources determine whether advancement is safe.
Account for concentration and osmolarity
Greater dextrose and amino-acid concentrations raise osmolarity. A classroom estimate can help screen an order, but final peripheral suitability depends on the complete formulation, access, validated policy, and vein tolerance. Central access does not make unlimited carbohydrate delivery metabolically safe.
Quick check
Submodule
Amino Acids, Lipid, and Growth
Protein and lipid support growth and neurodevelopment, but dose, formulation, rate, essential fatty-acid provision, clearance, and metabolic tolerance must be considered together.
- Preterm amino-acid guidance
- Pediatric protein calculations
- Lipid dose and advancement
- Essential fatty acids and triglyceride tolerance
age and evidence based g/kg
→product and age specific dose
→avoid rapid delivery
→actual intake and response
Use current preterm amino-acid limits
The 2023 ASPEN preterm guideline recommends against an initial amino-acid dose above 3 g/kg/day. For the maximal target, it recommends at least 3 g/kg/day without exceeding 3.5 g/kg/day. This replaces the older classroom practice of treating 4 g/kg/day as a routine universal target. Other pediatric age groups require individualized dosing based on growth, illness, losses, organ support, and the selected product.
Do not impose blanket protein restriction
Renal or hepatic dysfunction does not automatically justify a fixed 1 g/kg/day ceiling. Dialysis, continuous kidney replacement therapy, catabolism, wounds, ammonia handling, growth, and the underlying diagnosis can move protein needs in different directions. Use current disease-specific guidance and monitor response.
Advance lipid deliberately
ASPEN recommends daily advancement to 3 g/kg/day for preterm infants when soybean-oil or multicomponent lipid is used, while attending to composition and essential fatty-acid provision. Current SMOFlipid labeling begins at 0.5 to 1 g/kg/day from birth through 2 years and does not exceed 3 g/kg/day. Age, product, total energy, clearance, and clinical status govern the actual order.
Protect against rapid infusion
Rapid lipid infusion has caused severe decompensation in neonates and infants. For current SMOFlipid labeling, the hourly rate must not exceed 0.75 mL/kg/hour. ASPEN recommends a 1.2 micron filter and neonatal photoprotection. Separate infusion requires safeguards against pump programming and line-connection errors.
Quick check
Submodule
Electrolytes, Minerals, Vitamins, and Trace Elements
Growth, immature elimination, organ dysfunction, gastrointestinal losses, and product concentration make pediatric micronutrient design especially sensitive to weight and formulation details.
- Calcium and phosphorus for bone mineralization
- Sodium, potassium, magnesium, and acetate
- Age-specific multivitamins
- Trace-element adjustment
bone accretion and solubility
→losses, kidneys, medicines
→age and product label
→losses, cholestasis, duration
Balance growth with compatibility
Preterm infants have high calcium and phosphorus needs because substantial mineral accretion normally occurs late in gestation. The amount that can be delivered is limited by solubility, final concentration, amino-acid formulation, pH, salt form, temperature, order of mixing, storage, and infusion conditions. Calcium gluconate is generally preferred for PN compatibility.
Count both ions in phosphate products
Sodium phosphate contributes sodium and phosphate, while potassium phosphate contributes potassium and phosphate. Concentrations vary by product. Calculate mmol of phosphate and mEq of the counterion separately, then add both to the final daily electrolyte totals.
Use pediatric vitamin products and labeled dosing
Pediatric parenteral multivitamin dosing depends on product labeling and weight or age. An adult product is not an automatic substitute for an infant product. During shortages, use current ASPEN and ASHP recommendations rather than turning a temporary conservation plan into routine care.
Adjust trace elements selectively
Zinc needs can rise with diarrhea, ostomy output, burns, or wounds. Copper and manganese require careful review in cholestasis because biliary excretion is impaired, but complete omission can also create deficiency. Selenium, copper, zinc, and manganese decisions depend on weight, organ function, losses, duration, products, and measured trends when interpretable.
Quick check
Submodule
Compatibility, Aluminum, Filtration, and Photoprotection
A neonatal PN admixture can be mathematically correct and still unsafe because of precipitation, emulsion instability, light exposure, contamination, aluminum burden, or administration error.
- Calcium-phosphate solubility
- Two-in-one versus total nutrient admixture
- Aluminum exposure
- Filter, light, and administration safeguards
calcium, phosphate, pH, process
→sum total aluminum exposure
→current PN filtration
→neonatal bag and administration set
Validate the complete formulation
Calcium-phosphate solubility depends on amino-acid product and concentration, calcium and phosphate salts, pH, cysteine, other electrolytes, final volume, temperature, sequence, time, and storage. A clear bag does not prove safety. Use validated compatibility data and compounding-system limits for the exact formulation.
Do not force a total nutrient admixture
ASPEN notes that a total nutrient admixture is often not feasible for pediatric patients because high calcium and phosphorus requirements create compatibility and stability constraints. Lipid is commonly infused separately or co-administered by a validated Y-site process. Product-specific compatibility remains required.
Calculate the aluminum burden
Aluminum can enter PN through large- and small-volume products, especially certain mineral salts. Immature kidneys and prolonged exposure increase risk for neurologic and bone toxicity. FDA recommends total PN aluminum exposure not exceed 4 to 5 mcg/kg/day. Use measured or labeled concentrations as directed and sum every source.
Protect the entire administration path
ASPEN recommends a 1.2 micron filter for lipid and other PN formulations and photoprotection when lipid is used in neonates. Light protection should cover the validated container and administration set. Independent checks should confirm patient, route, pump channel, rate, line connection, filter, and protection from the pharmacy through the bedside.
Quick check
Submodule
Order Construction, Monitoring, and Transition
A pediatric PN order is a daily closed loop that connects growth goals, calculations, source products, the final container, actual delivery, laboratory trends, and enteral advancement.
- Daily order reconstruction
- Source volumes and final concentration
- Growth and metabolic monitoring
- Enteral transition and access preservation
weight, grams, volume, route
→sources, compatibility, label
→pump, filter, line, actual intake
→growth, labs, enteral progress
Build from the patient outward
Start with a verified dosing weight and total fluid allowance. Subtract non-PN fluids. Calculate amino acids, GIR and dextrose grams, lipid grams and volume, electrolytes, minerals, vitamins, trace elements, and sterile water. Confirm final concentration, osmolarity screen, compatibility, route, infusion time, and rate.
Compare more than laboratory values
Monitor actual intake, output, edema, daily or clinically appropriate weight, growth velocity, head circumference and length when relevant, glucose, electrolytes, calcium, magnesium, phosphorus, triglycerides, liver and kidney function, acid-base status, catheter findings, and feeding tolerance. Frequency changes with age, stability, acuity, and recent order changes.
Use trends to change one coherent plan
A high glucose value may reflect GIR, sepsis, stress, steroids, insulin delivery, or sampling contamination. Rising bilirubin may reflect infection, intestinal failure, lack of enteral stimulation, energy excess, or PN exposure. Review the whole pattern before changing a single nutrient in isolation.
Transition while preserving growth
Advance enteral nutrition when clinically safe, measure what is actually delivered, and reduce PN as enteral nutrients reliably replace intravenous delivery. Recalculate fluid and energy across both routes. Remove central access when it is no longer needed, while balancing infection risk against the possibility of premature removal in intestinal failure.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.